<DOC>
	<DOCNO>NCT01347944</DOCNO>
	<brief_summary>The purpose study collect clinical laboratory data patient affect intermediate 1 low risk Myelodysplastic Syndrome ( MDS ) associate deletion 5q prescribe Revlimid 31October 2008 present . Revlimid available Italy patient since October 2008 base local disposition Italian Drug Agency ( AIFA ) issue accord National law name 648/96 .</brief_summary>
	<brief_title>MORE - Monitoring Revlimid - Collecting Patient Information From Myelodysplastic Syndrome ( MDS ) Italian National Registry</brief_title>
	<detailed_description>There retrospective collection integration clinical laboratory data well prospective data collection patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>intermediate 1 low risk MDS patient associate : 1. transfusion dependency anemia ( least 2 unit per 8 week start Revlimid treatment ) 2 . 5q3133 deletion isolate associate chromosomal abnormality . patient serum creatinine &gt; 2.5mg/dl child bear potential female use adequate contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>MORE</keyword>
	<keyword>Monitoring Revlimid</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Transfusion-dependent anemia</keyword>
	<keyword>5q deletion</keyword>
	<keyword>lenalidomide</keyword>
</DOC>